Longer-lasting Botox competitor nabs FDA approval — can it compete with AbbVie's $2B cash cow?

Longer-lasting Botox competitor nabs FDA approval — can it compete with AbbVie's $2B cash cow?

Source: 
Endpoints
snippet: 

Revance Therapeutics announced Thursday that its first FDA approval has finally arrived for its Botox competitor, known as Daxxify, after initially submitting its original BLA way back in January 2020.